Seven Fleet Capital Management LP Acquires New Position in Eupraxia Pharmaceuticals Inc. $EPRX

Seven Fleet Capital Management LP bought a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 610,785 shares of the company’s stock, valued at approximately $4,037,289. Eupraxia Pharmaceuticals accounts for 0.0% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 29th biggest position. Seven Fleet Capital Management LP owned 0.94% of Eupraxia Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Royal Bank of Canada increased its position in shares of Eupraxia Pharmaceuticals by 21.1% during the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after purchasing an additional 59,683 shares during the period. JPMorgan Chase & Co. lifted its stake in Eupraxia Pharmaceuticals by 593.2% during the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after purchasing an additional 16,017 shares during the last quarter. Bank of America Corp DE grew its position in shares of Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after buying an additional 10,059 shares during the period. UBS Group AG raised its stake in shares of Eupraxia Pharmaceuticals by 155.4% in the third quarter. UBS Group AG now owns 95,756 shares of the company’s stock valued at $565,000 after buying an additional 58,257 shares during the period. Finally, Raymond James Financial Inc. boosted its position in Eupraxia Pharmaceuticals by 173.3% during the 3rd quarter. Raymond James Financial Inc. now owns 33,373 shares of the company’s stock valued at $197,000 after buying an additional 21,161 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Zacks Research raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Wall Street Zen lowered shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Finally, Stifel Nicolaus assumed coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They set a “buy” rating and a $25.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Eupraxia Pharmaceuticals Stock Down 9.2%

Shares of EPRX stock traded down $0.68 on Friday, reaching $6.68. 174,227 shares of the stock were exchanged, compared to its average volume of 275,790. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02. Eupraxia Pharmaceuticals Inc. has a twelve month low of $5.12 and a twelve month high of $9.32. The company has a market capitalization of $434.33 million, a price-to-earnings ratio of -6.55 and a beta of 1.08. The business’s 50 day moving average price is $6.60 and its 200 day moving average price is $7.04.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. As a group, sell-side analysts expect that Eupraxia Pharmaceuticals Inc. will post -0.87 earnings per share for the current fiscal year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.